Paolo Tombesi
2018 - INSMED
In 2018, Paolo Tombesi earned a total compensation of $2M as Chief Financial Officer at INSMED, a 7% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $270,000 |
|---|---|
| Option Awards | $975,001 |
| Salary | $442,620 |
| Stock Awards | $324,978 |
| Other | $11,229 |
| Total | $2,023,828 |
Tombesi received $975K in option awards, accounting for 48% of the total pay in 2018.
Tombesi also received $270K in non-equity incentive plan, $442.6K in salary, $325K in stock awards and $11.2K in other compensation.
Rankings
In 2018, Paolo Tombesi's compensation ranked 5,692nd out of 14,244 executives tracked by ExecPay. In other words, Tombesi earned more than 60.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,692 out of 14,244 | 60th |
Division Manufacturing | 2,151 out of 5,759 | 63rd |
Major group Chemicals And Allied Products | 794 out of 2,122 | 63rd |
Industry group Drugs | 662 out of 1,811 | 63rd |
Industry Pharmaceutical Preparations | 511 out of 1,385 | 63rd |
Source: SEC filing on April 4, 2019.
Tombesi's colleagues
We found six more compensation records of executives who worked with Paolo Tombesi at INSMED in 2018.
2018
William Lewis
INSMED
Chief Executive Officer
2018
Roger Adsett
INSMED
Chief Commercial Officer
2018
Paul Streck
INSMED
Chief Medical Officer
2018
Christine Pellizzari
INSMED
Chief Legal Officer
2018
S Schaeffer
INSMED
Chief People Strategy Officer
2018
John Goll
INSMED
Former Principal Financial Officer
News
Turning Point Therapeutics CEO Athena Countouriotis' 2021 pay rises 11% to $17M
April 29, 2022
Epizyme CEO Robert Bazemore's 2020 pay jumps 103% to $8.5M
April 29, 2021
Epizyme CEO Robert Bazemore's 2019 pay rises 14% to $4.2M
April 17, 2020
INSMED CEO William Lewis' 2019 pay jumps 21% to $7.2M
March 31, 2020
INSMED CEO William Lewis' 2018 pay jumps 37% to $5.9M
April 4, 2019